Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : Veklury Lowers Hospitalization Risk in COVID-19 Patients in Phase 3 Study

09/22/2021 | 12:04pm EST


© MT Newswires 2021
All news about GILEAD SCIENCES, INC.
10:31aGILEAD SCIENCES : Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant
PU
11/30NRX Pharmaceuticals Shares Slide 16% After Soaring on COVID-19 Drug, Vaccine Updates
MT
11/30Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..
MT
11/30Regeneron's COVID-19 antibody drug may be less effective against Omicron
RE
11/30Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Hi..
AQ
11/29NRX Pharmaceuticals Soars After Saying Zyesami Outperformed Remdesivir for Critical COV..
MT
11/29Gilead Sciences Selects Amazon Web Services as Cloud Provider
MT
11/29Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Hi..
BU
11/24Gilead Sciences' Trodelvy (sacituzumab govitecan) Granted European Commission Marketing..
AQ
11/24Gilead Sciences, Merck Pause Phase 2 HIV Trial
MT
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 26 515 M - -
Net income 2021 7 187 M - -
Net Debt 2021 22 390 M - -
P/E ratio 2021 12,0x
Yield 2021 4,11%
Capitalization 86 465 M 86 465 M -
EV / Sales 2021 4,11x
EV / Sales 2022 4,30x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 68,93 $
Average target price 75,95 $
Spread / Average Target 10,2%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE331.48%84 953
WUXI APPTEC CO., LTD.28.27%66 734
REGENERON PHARMACEUTICALS31.76%66 553
VERTEX PHARMACEUTICALS-20.90%47 530
BEIGENE, LTD.34.50%32 613